UBT-251 vs Retatrutide
UBT-251 is a real investigational triple-hormone agonist — the same GLP-1/GIP/glucagon class as retatrutide — that Novo Nordisk licensed outside Greater China in 2025. It's a once-weekly injection, not the 'oral GLP-1 pill' circulating online. But the specific weight-loss numbers going viral for it do not come from any peer-reviewed study.
How It Works
Slows gastric emptying and blunts appetite, the same axis semaglutide and tirzepatide use to cut food intake.
Enhances glucose-dependent insulin secretion and is thought to improve the tolerability of the GLP-1 effect — the second arm shared with tirzepatide and retatrutide.
Raises energy expenditure and mobilises hepatic fat. Adding this third receptor is what separates a triple agonist like UBT-251 or retatrutide from a dual agonist.
UBT-251 is an injectable, not an oral pill, despite viral claims to the contrary. Specific dose amounts and the exact schedule circulating online are not confirmable in any peer-reviewed publication or public trial registry we could verify — treat them as unverified.
What the Data Shows
Here is the crucial caveat the viral posts skip: UBT-251 has no peer-reviewed weight-loss data, so it cannot honestly be placed on this chart. The specific figures circulating for it (a ~19.7% result at 24 weeks) trace only to an unverified conference abstract with no PubMed record we could confirm. The bars below are the established, peer-reviewed comparators UBT-251 is being measured against — each one has a PMID you can check. When UBT-251's own trial results are published in a journal, they can join this chart; until then, treat any UBT-251 number as marketing, not evidence.
Key Takeaways
- UBT-251 is a once-weekly subcutaneous triple agonist (GLP-1 / GIP / glucagon) — the same receptor class as retatrutide, and an injection, not the 'oral pill' claimed online.
- Novo Nordisk licensed rights outside Greater China from United Biotechnology (a subsidiary of The United Laboratories) in 2025; it did not originate the molecule.
- The established comparators it is measured against — retatrutide, tirzepatide and semaglutide — all have peer-reviewed phase-2/3 weight-loss data (PMIDs 37366315, 35658024, 33567185).
- Retatrutide's headline 24.2% is a 48-week figure, so any side-by-side using it against a 24-week UBT-251 number is comparing different durations.
- UBT-251's actual weight-loss efficacy is not established. The specific figures circulating online (≈19.7% at 24 weeks, −17.5 kg, a 2.0% placebo arm) trace only to an unverified conference abstract with no PubMed record we could confirm — treat them as unverified.
- No head-to-head trial of UBT-251 vs retatrutide exists, and there is no peer-reviewed UBT-251 dataset to run even a cross-trial comparison against.
- Detailed trial specifics circulating online (patient counts, dosing schedules, durations) are not confirmed by any verifiable registry or publication we could cite here.
- UBT-251's long-term weight loss, weight-regain profile, full safety, and cardiometabolic outcomes are all unknown.
- UBT-251 is investigational — not approved, not for sale, and not a substitute for any prescribed therapy.
Frequently Asked Questions
Is UBT-251 an oral GLP-1 pill?
No. UBT-251 is given as a once-weekly subcutaneous injection in its trials, and it is a triple agonist (GLP-1, GIP and glucagon) — not a GLP-1-only drug. The 'oral pill' framing circulating on social media is inaccurate.
Is UBT-251 better than retatrutide?
There is no way to say, because UBT-251 has no peer-reviewed weight-loss data. The viral '24% vs 19.7%' comparison relies on figures that trace only to an unverified conference abstract, and it also mismatches durations — retatrutide's published 24.2% is a 48-week result. No head-to-head trial has been run, and no verifiable UBT-251 efficacy figure exists to compare.
Who makes UBT-251?
It was developed by United Biotechnology, a subsidiary of The United Laboratories (TUL). Novo Nordisk licensed the rights outside Greater China in a March 2025 agreement, while the developer keeps rights in mainland China, Hong Kong, Macau and Taiwan.
How does UBT-251 work?
It activates three receptors at once — GLP-1 and GIP (appetite control and glucose-dependent insulin release) plus glucagon (increased energy expenditure and hepatic fat mobilisation). That is the same triple-agonist mechanism retatrutide uses.
Can I buy UBT-251?
No. UBT-251 is an investigational drug still in clinical trials. It is not approved by any regulator and is not sold by any vendor — anything marketed under that name should be treated as unverified.
🔬 Research-Grade Source
Swiss Chems publishes third-party HPLC COAs for selected products — vendor-published, a claim to verify. HighPeptides' primary vendor reference for peptides.
Browse Swiss Chems →Affiliate links — support HighPeptides at no extra cost.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Peer-Reviewed References
Educational purposes only. Not medical advice.
UBT-251 is an investigational compound in clinical trials — not approved by any regulator and not available for purchase.
The weight-loss figures circulating online for UBT-251 could not be traced to a peer-reviewed publication or verifiable PubMed record and should be treated as unverified until a journal publishes the trial. The only efficacy numbers on this page belong to the established comparators (retatrutide, tirzepatide, semaglutide), each cited to a PMID; those are not head-to-head with UBT-251.